Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389631 | 0.93 | SYK (0.57) | SYKCDC7 | |
| SCHEMBL19297747 | 0.86 | AURKA (0.52) | SYK | |
| SCHEMBL27631763 | 0.83 | SYK (0.62) | SYK | |
| SCHEMBL19297729 | 0.83 | SYK (0.62) | SYK | |
| SCHEMBL19297721 | 0.83 | SYK (0.55) | SYK | |
| SCHEMBL12439737 | 0.83 | SYK (0.58) | SYKROCK2ROCK1CDC7ULK1 | |
| SCHEMBL19297744 | 0.83 | SYK (0.47) | SYK | |
| SCHEMBL19297727 | 0.81 | SYK (0.54) | SYKROCK2ROCK1CDC7ULK1 | |
| SCHEMBL1973780 | 0.81 | SYK (0.77) | SYKROCK2ROCK1CDC7ULK1 | |
| SCHEMBL12389639 | 0.79 | SYK (0.58) | SYKCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751893-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | claimed |
| US-9598432-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8809341-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110190271-A1 | 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7884111-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884111-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | SYK 4427/4885ROCK2 2045/4885ROCK1 2776/4885 |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | SYK 4427/4885ROCK2 2045/4885ROCK1 2776/4885 |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | SYK 4427/4885ROCK2 2045/4885ROCK1 2776/4885 |
| US-20110190271-A1 | 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents | MKI67, TYMP, PCNA | SYK 4427/4885ROCK2 2045/4885ROCK1 2776/4885 |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | SYK 4427/4885ROCK2 2045/4885ROCK1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.